PL3215511T3 - Podstawione pirazolo(1,5-a)pirymidyny i ich zastosowanie w leczeniu zaburzeń medycznych - Google Patents
Podstawione pirazolo(1,5-a)pirymidyny i ich zastosowanie w leczeniu zaburzeń medycznychInfo
- Publication number
- PL3215511T3 PL3215511T3 PL15857508.4T PL15857508T PL3215511T3 PL 3215511 T3 PL3215511 T3 PL 3215511T3 PL 15857508 T PL15857508 T PL 15857508T PL 3215511 T3 PL3215511 T3 PL 3215511T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrimidines
- treatment
- medical disorders
- substituted pyrazolo
- pyrazolo
- Prior art date
Links
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076062P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/059541 WO2016073895A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3215511T3 true PL3215511T3 (pl) | 2024-08-12 |
Family
ID=55909884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15857508.4T PL3215511T3 (pl) | 2014-11-06 | 2015-11-06 | Podstawione pirazolo(1,5-a)pirymidyny i ich zastosowanie w leczeniu zaburzeń medycznych |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10570135B2 (pl) |
| EP (2) | EP3215511B1 (pl) |
| JP (2) | JP6734860B2 (pl) |
| KR (1) | KR102662215B1 (pl) |
| CN (2) | CN107001379B (pl) |
| AU (1) | AU2015342887B2 (pl) |
| CA (1) | CA2966583A1 (pl) |
| DK (1) | DK3215511T3 (pl) |
| EA (1) | EA201790995A1 (pl) |
| ES (1) | ES2984482T3 (pl) |
| FI (1) | FI3215511T3 (pl) |
| HR (1) | HRP20240644T1 (pl) |
| HU (1) | HUE066864T2 (pl) |
| IL (1) | IL252053B2 (pl) |
| LT (1) | LT3215511T (pl) |
| MX (1) | MX394094B (pl) |
| PL (1) | PL3215511T3 (pl) |
| PT (1) | PT3215511T (pl) |
| RS (1) | RS65642B1 (pl) |
| SI (1) | SI3215511T1 (pl) |
| SM (1) | SMT202400187T1 (pl) |
| WO (1) | WO2016073895A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2649075T1 (sl) * | 2010-12-08 | 2018-10-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Substituirani pirazolopirimidini kot aktivatorji glukocerebrozidaze |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| PL3215511T3 (pl) * | 2014-11-06 | 2024-08-12 | Bial-R&D Investments, S.A. | Podstawione pirazolo(1,5-a)pirymidyny i ich zastosowanie w leczeniu zaburzeń medycznych |
| CN108473498B (zh) | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| EP3429590A4 (en) * | 2016-03-16 | 2020-02-19 | Lysosomal Therapeutics Inc. | METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE |
| EP3440083A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| WO2017176962A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| CN109311887B (zh) | 2016-04-06 | 2022-09-13 | Bial研发投资股份有限公司 | 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| MX389579B (es) | 2016-05-05 | 2025-03-20 | Bial R&D Invest S A | IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS |
| EP3535273A1 (en) | 2016-11-02 | 2019-09-11 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
| CN110325516A (zh) | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | 杂芳基化合物和它们的用途 |
| CA3061236A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| US12064414B2 (en) * | 2017-12-20 | 2024-08-20 | Aizant Drug Research Solutions Private Limited. | Stable amorphous Eliglustat premix and process for the preparation thereof |
| US20200339587A1 (en) * | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| EP3747885A4 (en) | 2018-01-31 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| IT201800006067A1 (it) * | 2018-06-06 | 2019-12-06 | Nuovi inibitori della diidroortato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide. | |
| US11414431B2 (en) * | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| CN111217816B (zh) * | 2018-11-27 | 2022-08-16 | 中国科学院上海药物研究所 | 一类flt3激酶抑制剂及其制备和应用 |
| GB202211999D0 (en) * | 2022-08-17 | 2022-09-28 | Mironid Ltd | Compounds and their use as PDE4 activators |
| WO2025198486A1 (en) | 2024-03-22 | 2025-09-25 | BIAL – R&D Investments, S.A. | Process for preparing a pyrazolo[1,5-a]pyrimidinyl carboxamide compound |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
| JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物 |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| JP4070966B2 (ja) | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
| ATE307812T1 (de) | 2001-10-22 | 2005-11-15 | Pfizer | Imidazopyridinverbindungen als 5-ht4- rezeptormodulatoren |
| EP1481977A4 (en) | 2002-03-01 | 2006-02-01 | Astellas Pharma Inc | NITROGENIC HETEROCYCLIC COMPOUND |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| BR0314584A (pt) | 2002-09-20 | 2005-08-09 | Pfizer | Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| CN1906162B (zh) | 2003-11-12 | 2012-05-23 | 阿米库斯治疗学公司 | 用于治疗戈谢病的羟基哌啶衍生物 |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| AU2005212096B2 (en) | 2004-02-18 | 2010-12-16 | Msd K.K. | Nitrogenous fused heteroaromatic ring derivative |
| NZ551424A (en) | 2004-05-14 | 2009-10-30 | Childrenaes Cancer Inst Austra | Small molecule inhibitors for MRP1 and other multidrug transporters |
| CA2571487C (en) | 2004-06-21 | 2013-04-30 | F. Hoffmann-La Roche Ag | Pyrrazolo-pyrimidine derivatives |
| DE502005003491D1 (de) | 2004-08-02 | 2008-05-08 | Sanol Arznei Schwarz Gmbh | Carboxamide des indolizins und seiner aza- und diazaderivate |
| DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| DE602006010320D1 (de) | 2005-01-19 | 2009-12-24 | Merck & Co Inc | Bicyclische pyrimidine als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes |
| MX2007009106A (es) | 2005-02-11 | 2007-09-11 | Hoffmann La Roche | Derivados de pirazolo-pirimidina como antagonistas del receptor de glutamato metabotropico 2. |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| US7767854B2 (en) | 2005-04-21 | 2010-08-03 | Dainippon Sumitomo Pharma Co., Ltd. | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1931675B1 (en) | 2005-10-06 | 2015-01-14 | Merck Sharp & Dohme Corp. | Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors |
| ATE517874T1 (de) | 2005-10-21 | 2011-08-15 | Exelixis Inc | Pyrimidinone als modulatoren von caseinkinase ii (ck2) |
| JP2009518340A (ja) | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | ＥｐｈＢおよびＶＥＧＦＲ２キナーゼ阻害剤としてのピラゾロ［１，５−ａ］ピリジン−３−カルボン酸 |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| US7829579B2 (en) | 2006-06-23 | 2010-11-09 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| US7553846B2 (en) | 2006-08-07 | 2009-06-30 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| CA2670044A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| EP2137187A1 (en) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| WO2008157575A1 (en) | 2007-06-21 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| WO2009070567A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| US20110118236A1 (en) | 2008-03-25 | 2011-05-19 | Michiyo Mochizuki | Heterocyclic compound |
| EP2273992B1 (en) | 2008-05-01 | 2016-05-25 | Glaxosmithkline LLC | Quinolines and related analogs as sirtuin modulators |
| WO2010043893A1 (en) | 2008-10-14 | 2010-04-22 | Astrazeneca Ab | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections |
| BRPI0914404A2 (pt) * | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| SI2649075T1 (sl) * | 2010-12-08 | 2018-10-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Substituirani pirazolopirimidini kot aktivatorji glukocerebrozidaze |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| EP2688872A4 (en) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| AU2012295805B2 (en) | 2011-08-18 | 2017-05-04 | Nippon Shinyaku Co., Ltd. | Heterocyclic derivative and pharmaceutical drug |
| BR112014005110A2 (pt) | 2011-09-02 | 2017-04-18 | Bayer Ip Gmbh | pirimidinas aneladas substituídas e utilização das mesmas |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CA2852936A1 (en) | 2011-10-20 | 2013-04-25 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013134079A1 (en) * | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| HUE036040T2 (hu) | 2012-03-09 | 2018-06-28 | Lexicon Pharmaceuticals Inc | Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére |
| CA2868484A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
| BR112014029404A2 (pt) | 2012-05-31 | 2017-06-27 | Hoffmann La Roche | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção |
| BR112014030147B1 (pt) | 2012-06-22 | 2019-10-15 | Sumitomo Chemical Company, Limited | Compostos heterocíclicos fundidos, composição e método para controlar pestes |
| WO2014025651A1 (en) * | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
| JP2015532650A (ja) | 2012-09-05 | 2015-11-12 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用 |
| NZ707432A (en) | 2012-11-16 | 2020-01-31 | Univ Health Network | Pyrazolopyrimidine compounds |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| ES2884030T3 (es) * | 2012-12-07 | 2021-12-10 | Vertex Pharma | 2-amino-N-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa |
| KR20140086002A (ko) | 2012-12-28 | 2014-07-08 | 한미약품 주식회사 | Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체 |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| WO2015012328A1 (ja) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015026574A1 (en) | 2013-08-20 | 2015-02-26 | Bristol-Myers Squibb Company | Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EP3122726B1 (en) | 2014-03-27 | 2018-08-29 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| PL3215511T3 (pl) | 2014-11-06 | 2024-08-12 | Bial-R&D Investments, S.A. | Podstawione pirazolo(1,5-a)pirymidyny i ich zastosowanie w leczeniu zaburzeń medycznych |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| EP3317282B1 (en) | 2015-07-01 | 2020-12-09 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017004405A1 (en) | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017040877A1 (en) | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| KR102782807B1 (ko) | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| EP3416967B1 (en) | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Therapeutic compounds, compositions and methods of use thereof |
| EP3440083A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| CN109311887B (zh) | 2016-04-06 | 2022-09-13 | Bial研发投资股份有限公司 | 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 |
| EP3452045A1 (en) | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| MX389579B (es) | 2016-05-05 | 2025-03-20 | Bial R&D Invest S A | IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS |
| WO2017192929A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| US20200339587A1 (en) | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
-
2015
- 2015-11-06 PL PL15857508.4T patent/PL3215511T3/pl unknown
- 2015-11-06 EA EA201790995A patent/EA201790995A1/ru unknown
- 2015-11-06 DK DK15857508.4T patent/DK3215511T3/da active
- 2015-11-06 CN CN201580068129.9A patent/CN107001379B/zh active Active
- 2015-11-06 SM SM20240187T patent/SMT202400187T1/it unknown
- 2015-11-06 HR HRP20240644TT patent/HRP20240644T1/hr unknown
- 2015-11-06 SI SI201532014T patent/SI3215511T1/sl unknown
- 2015-11-06 CA CA2966583A patent/CA2966583A1/en active Pending
- 2015-11-06 ES ES15857508T patent/ES2984482T3/es active Active
- 2015-11-06 MX MX2017005940A patent/MX394094B/es unknown
- 2015-11-06 US US15/523,769 patent/US10570135B2/en active Active
- 2015-11-06 KR KR1020177015300A patent/KR102662215B1/ko active Active
- 2015-11-06 IL IL252053A patent/IL252053B2/en unknown
- 2015-11-06 PT PT158575084T patent/PT3215511T/pt unknown
- 2015-11-06 RS RS20240536A patent/RS65642B1/sr unknown
- 2015-11-06 EP EP15857508.4A patent/EP3215511B1/en active Active
- 2015-11-06 EP EP24166780.7A patent/EP4406616A3/en not_active Withdrawn
- 2015-11-06 AU AU2015342887A patent/AU2015342887B2/en active Active
- 2015-11-06 LT LTEPPCT/US2015/059541T patent/LT3215511T/lt unknown
- 2015-11-06 HU HUE15857508A patent/HUE066864T2/hu unknown
- 2015-11-06 JP JP2017544549A patent/JP6734860B2/ja active Active
- 2015-11-06 CN CN202211277924.7A patent/CN115925711A/zh active Pending
- 2015-11-06 FI FIEP15857508.4T patent/FI3215511T3/fi active
- 2015-11-06 WO PCT/US2015/059541 patent/WO2016073895A1/en not_active Ceased
-
2017
- 2017-02-23 US US15/440,107 patent/US9732089B2/en active Active
-
2020
- 2020-01-03 US US16/733,598 patent/US11091492B2/en active Active
- 2020-07-10 JP JP2020119444A patent/JP7519221B2/ja active Active
-
2021
- 2021-07-07 US US17/369,507 patent/US11932645B2/en active Active
-
2024
- 2024-02-09 US US18/437,558 patent/US20250066364A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3215511T (lt) | Pakeistieji pirazolo(1,5-a)pirimidinai ir jų panaudojimas medicininių sutrikimų gydymui | |
| EP3215509A4 (en) | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | |
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| IL259751B (en) | Polycyclic compounds and their use in the treatment of immune disorders | |
| IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
| IL262177B (en) | Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders | |
| IL262698B (en) | [1,2-b]Amidazo-converted pyridazines, [1,5-b]imidazo-converted pyridazines, related compounds and their use for the treatment of medical disorders | |
| IL246579B (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| EP3215510A4 (en) | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | |
| EP3344632A4 (en) | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders | |
| EP3452480A4 (en) | SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| IL260221A (en) | Indolinone compounds and their use for the treatment of leiftic diseases | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| ZA201905402B (en) | Compounds and their use in the treatment of schistosomiasis | |
| ZA201701207B (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| EP3344625A4 (en) | THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE | |
| HK40085266B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40004413A (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| HK40006031A (en) | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| ZA201704727B (en) | New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |